Navigation Links
WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference
Date:12/8/2011

FREMONT, Calif., Dec. 8, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today announced that the company plans to deliver its corporate presentation at the Oppenheimer 22nd Annual Healthcare Conference at the Waldorf-Astoria, New York, NY, December 13-14, 2011.

The Company is scheduled to present on Tuesday, December 13, 2011 from 3:35-3:50 p.m. Eastern Time.  The presentation will be webcast live and will be available for replay at the Company's website at www.wafergen.com.

For more information about the conference, go to http://www.opco.com/conferences/healthcare11/index.html

 

About WaferGen and the SmartChip Real-Time PCR System
WaferGen Biosystems, Inc., an emerging genomic analysis company in the early stage of commercialization, offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and Single Nucleotide Polymorphism (SNP) genotyping. WaferGen also offers Quick-Turnaround SmartChip Custom (User-Defined) Panels to enable validation studies of specific genes of interest through customization of high-throughput, real-time PCR SmartChip assay panels—all on a quick-turnaround basis.

In addition, the Company offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com

 

WaferGen Contacts
510-651-4450

Don Huffman, CFO
don.huffman@wafergen.com

Media:  Joyce Strand
joyce.strand@wafergen.com

 


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
2. WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
3. WaferGen Announces $30 Million Financing
4. WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing
5. WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels
6. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
7. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
8. WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System
9. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
10. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
11. WaferGen Closes on Private Financings of Approx. $6.2 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):